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Abstract
Introduction Although mefloquine use is known to be
associated with a risk of severe neuropsychiatric adverse
reactions that are often preceded by prodromal symptoms,
specific combinations of neurologic or psychiatric reac-
tions associated with mefloquine use are not well described
in the literature. This study sought to identify a distinct
neuropsychiatric syndrome class associated with meflo-
quine use in reports of adverse events.
Methods Latent class modeling of US Food and Drug
Administration Adverse Event Reporting System (FAERS)
data was performed using indicators defined by the Medi-
cal Dictionary for Regulatory Activities neurologic and
psychiatric high-level group terms, in a study dataset of
FAERS reports (n = 5332) of reactions to common anti-
malarial drugs.
Results A distinct neuropsychiatric syndrome class was
identified that was strongly and significantly associated
with reports of mefloquine use (odds ratio = 3.92, 95%
confidence interval 2.91–5.28), defined by a very high
probability of symptoms of deliria (82.7%) including
confusion and disorientation, and a moderate probability of
other severe psychiatric and neurologic symptoms includ-
ing dementia and amnesia (18.6%) and seizures (18.1%).
The syndrome class was also associated with symptoms
that are considered prodromal including anxiety, depres-
sion, sleep disturbance, and abnormal dreams, and neuro-
logical symptoms such as dizziness, vertigo, and
paresthesias.
Conclusions This study confirms in FAERS reports the
existence of a severe mefloquine neuropsychiatric syn-
drome class associated with common symptoms that may
be considered prodromal. Clinical identification of the
characteristic symptoms of this syndrome class may aid in
improving case finding in pharmacovigilance studies of
more serious adverse reactions to the drug.
Key Points
Some reports of adverse effects from mefloquine
define a syndrome class characterized by symptoms
of deliria.
This syndrome class is associated with additional
symptoms including some that may be prodromal.
1 Introduction
Use of mefloquine, a synthetic quinoline derivative anti-
malarial, has been well known for many decades to be
associated with a risk of occasionally severe, neuropsy-
chiatric adverse reactions [1]. When used prophylactically
to prevent malaria, certain of these reactions may be con-
sidered prodromal, and as described in a recent boxed
warning mandated by the US Food and Drug
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Administration (FDA) in 2013, may predict the develop-
ment of more serious adverse effects, including potentially
disabling psychiatric and neurological symptoms that may
persist or become permanent after mefloquine has been
discontinued [2, 3].
Symptoms consistent with prodromal reactions to
mefloquine, which include very common symptoms of
sleep disturbance and abnormal dreams, which are reported
in greater than 10% of users, and common symptoms of
anxiety and depression, which are reported in between 1
and 10% of users [2], may occur independently in settings
such as international travel [4] and military operations [5]
where mefloquine may be used prophylactically. Such
prodromal reactions may also be plausibly reported as a
result of reporting bias, or because of nocebo effects [6].
Certain symptoms consistent with those of the mefloquine
prodrome may also occur from other drugs in settings of
mefloquine use. For example, two other antimalarial drugs
commonly used for prophylaxis of chloroquine-resistant
malaria, atovaquone-proguanil and doxycycline, are also
associated with symptoms of sleep disturbance and
abnormal dreams [7], although these are reported less
commonly than with mefloquine [8–10]. Similarly,
chloroquine has also long been associated with symptoms
similar to those caused by mefloquine [11, 12], although as
with atovaquone-proguanil and doxycycline, their occur-
rence with the use of chloroquine is not accompanied by
warnings to discontinue the drug at their onset.
Owing to the perceived ubiquity of such symptoms in
settings of mefloquine use, the unique guidance applicable
to mefloquine to discontinue the drug at the onset of pro-
dromal symptoms such as sleep disturbance, abnormal
dreams, anxiety, and depression may risk being minimized
or overlooked [2]. Similarly, as demonstrated by case
reports [13–15], such symptoms may be misattributed by
the patient or the clinician to causes other than to meflo-
quine. In each case, this may potentially reduce the
effectiveness of regulatory guidance that the drug be dis-
continued at their onset [2].
While US regulators at the FDA have noted that more
serious neurologic reactions to mefloquine are typically
accompanied by lasting psychiatric symptoms [3, 16],
specific combinations of neurologic and psychiatric reac-
tions associated with mefloquine use are not well described
in the literature. The absence in the literature of a well-
characterized and specific syndrome of neuropsychiatric
adverse reactions associated with mefloquine use may risk
such combinations of reactions confounding the diagnosis
of numerous other neuropsychiatric disorders [17, 18],
which may consequently limit the specificity of case find-
ing in pharmacovigilance studies of adverse reactions.
This study therefore sought to identify a distinct neu-
ropsychiatric syndrome class associated with reports of
adverse reactions from mefloquine use. This study further
sought to confirm the association of this syndrome with
prodromal symptoms, and to identify other specific symp-
toms commonly associated with it that might inform
improvements in case finding.
2 Methods
Latent class modeling (LCM) is a statistical method
enabling the grouping of individuals into one or more
distinct classes on the basis of responses to a finite number
of indicators, such as the presence or absence of various
reported symptoms [19]. LCM is a commonly accepted
method for improving accuracy in psychiatric diagnosis in
the absence of an objective ‘‘gold standard’’ [20]. Although
the reporting of drug adverse reactions may involve
selecting from potentially thousands of distinct medical
terms, these may be categorized into a manageable number
by means of the Medical Dictionary for Regulatory
Activities (MedDRA) vocabulary, which translates repor-
ted reactions into standard terminology known as lowest
level terms, and groups these into medically similar or
equivalent preferred terms (PTs) [21]. The MedDRA fur-
ther categorizes PTs multiaxially into one or more of 26
top-level system organ classes (SOCs), and within each
SOC, to typically one of a few dozen distinct high-level
group terms (HLGTs) [21], thus making the presence or
absence of reactions categorized at the SOC or HLGT level
of potential utility as indicators in LCM.
In this analysis, both SOC- and HLGT-level indicators
were used in conducting case-level LCM among drug
adverse events reported to the FDA. Reports used in this
analysis included those for the three antimalarial drugs
commonly used in the prophylaxis of chloroquine-resistant
malaria, mefloquine, atovaquone-proguanil, and doxycy-
cline; and as controls, those for chloroquine and the anti-
motility agent loperamide, a common co-exposure in set-
tings where antimalarials are used [22].
Descriptive statistical analyses were conducted using
STATA Version 14 (StataCorp, College Station, TX,
USA), and LCM was conducted using MPLUS Version 7.4
(Muthen & Muthen, Los Angeles, CA, USA).
2.1 Study Data
Reports of adverse reactions are maintained by the FDA in
the FDA Adverse Event Reporting System (FAERS) [23].
Study data were obtained by querying the Qscan FDA
database (DrugLogic, Reston, VA, USA), a commercial
aggregator of publicly available FAERS data, for all
FAERS reports listing mefloquine, atovaquone-proguanil,
doxycycline, chloroquine, and loperamide or their common
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generic and trade variants as suspect or non-suspect drugs
through 2012, the year prior to the FDA boxed warning.
Duplicate reports based on same age, sex, and FDA receipt
dates were automatically excluded from the query.
2.2 MedDRA Categorization of FAERS Report
Reactions
Where reactions in historical FAERS reports did not match
a current MedDRA PT, these were updated to the current
MedDRA vocabulary if these matched a current lowest
level term, or where there was no match, manually to a
lexical variant of a current lowest level term. Where a PT
was multiaxial, PT assignment was prioritized to the SOC
psychiatric disorders and nervous system disorders, in that
order. Categorized reactions of a general, social, or pro-
cedural nature (i.e., SOCs general disorders and adminis-
tration-site conditions; investigations; injury, poisonings,
and procedural complications; surgical and medical pro-
cedures; and social circumstances) were excluded. Reac-
tions describing congenital and perinatal conditions (i.e.,
SOCs congenital, familial, and genetic disorders; and
pregnancy, puerperium, and perinatal conditions), neo-
plastic conditions (i.e., SOC neoplasms benign, malignant
and unspecified including cysts and polyps), immune and
infectious disorders (i.e., SOCs immune system disorders;
and infections and infestations), and conditions of the
reproductive system (i.e., SOC reproductive system and
breast disorders) were also excluded.
For each FAERS report, binary indicators corresponding
to the 15 remaining SOCs, and to individual HLGTs within
the psychiatric and nervous system disorder SOCs, were
created on the basis of reported PTs.
2.3 Study Datasets
By drug, datasets were created collapsing by case number
any positive response in binary SOC- and HLGT-level
indicators across original and subsequent FAERS reports.
By case, the minimum of reported age (when not unknown)
was assigned as case age; sex was assigned as male,
female, or unknown; and for the three primary study drugs
mefloquine, atovaquone-proguanil, and doxycycline, the
indication was assigned as either for malaria prophylaxis or
other/unknown. To exclude neonatal cases potentially due
to maternal exposure, cases less than 1 year of age were
excluded. Datasets by drug were then pooled, and to ensure
independence in subsequent LCM, cases appearing in
multiple study drug datasets were excluded. Two study
datasets were created from the pooled dataset: the primary
dataset consisting of mefloquine, atovaquone-proguanil,
and doxycycline cases; and a control dataset consisting of
chloroquine and loperamide cases.
2.4 Latent Class Indicator Selection
To permit the data-driven selection of specific indicators
for the final LCM, initial latent class models were first
estimated from SOC-level indicators in the primary dataset
with greater than 2% overall prevalence with the aim of
identifying broad neuropsychiatric classes of reaction from
which specific neuropsychiatric HLGT-level indicators
would then be selected.
Two separate models were first estimated to assess for
convergent results across models: the first, a fully condi-
tionally dependent (full) model in which conditional
dependence was permitted between all indicator pairs; and
second, a partially conditionally dependent (partial) model
in which conditional dependence was permitted between
selected indicator pairs. For the partial model, these were
iteratively fit, specifying conditional dependence between
SOC-level indicator pairs with significant pairwise bivari-
ate residuals (Pearson v2[ 1.96), until a final model could
be estimated with non-significant pairwise bivariate resid-
uals. Among each model, fit statistics were compared, with
the final model selection made based on Bayesian infor-
mation criteria (BIC) [19]. The partial model was evaluated
for evidence of residual conditional dependence by means
of multiple, random probability-weighted pseudoclass
assignment, whereby SOC-level indicators with Bonfer-
roni-adjusted significant p values from pairwise logistic
regression in five or more of 100 draws by pseudoclass
were deemed to exhibit significant conditional dependence.
From each selected model, multiple neuropsychiatric
classes were then identified based on relatively elevated
conditional probabilities for psychiatric and nervous sys-
tem disorder SOC-level indicators. Among cases with the
most-likely membership in the identified neuropsychiatric
classes, neuropsychiatric HLGT-level indicators were then
similarly evaluated for evidence of differential measure-
ment by drug by means of multiple, random probability-
weighted pseudoclass assignment [24]. HLGT-level indi-
cators free of evidence of significant differential measure-
ment across model neuropsychiatric classes, and with
greater than 2% overall prevalence, were considered for
selection for the final LCM.
2.5 HLGT-Level LCM
Latent class models with two through four classes were
estimated from the primary dataset from the selected
neuropsychiatric HLGT-level indicators, permitting pair-
wise conditional dependence between all indicators, with
the final model selection made based on BIC. To account
for uncertainty in class membership, association of HLGT-
level class with drug was assessed by corrected three-step
testing in MPLUS, per published methods [25] with results
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reported as odds ratios (ORs) and 95% confidence intervals
(95% CIs).
3 Results
The number of cases by drug and final dataset are shown in
Fig. 1. When pooled, 196 of the 12,674 cases (1.5%) were
excluded for listing multiple study drugs. The sex and age
group of study cases by drug are shown in Table 1. The age
and sex distribution of cases varied significantly by v2 test
by drug for age group (p\0.001) and for sex (p\0.001)
in both the primary dataset and the pooled data overall. In
the primary dataset, the distribution of reported indication
also varied significantly by v2 test by drug (p\0.001), as
shown in Table 2.
3.1 SOC-Level Modeling
Total numbers and proportions of cases with reported
reactions in each of the 15 study SOCs were tabulated by
drug in the primary dataset and are shown in Table 3. The
proportions of reported reactions varied significantly by v2
test by drug across all SOCs (all p\ 0.05). By drug, the
most commonly reported reactions were within the psy-
chiatric disorders SOC for mefloquine (56.5% of cases,
most commonly the PT anxiety), the nervous system dis-
orders SOC for atovaquone-proguanil (29.1% of cases,
most commonly the PT headache), and the gastrointestinal
disorders SOC for doxycycline (31.4% of cases, most
commonly the PT nausea). Reactions were reported in
fewer than 2% of cases overall within two SOCs, ear and
labyrinth disorders, and endocrine disorders, which were
excluded from subsequent LCM.
In the primary dataset, reactions within the nervous
system disorder SOC were reported for 20 HLGTs at fre-
quencies ranging from 0.03 to 22.2%, and within the psy-
chiatric disorder SOC for 23 HLGTs at frequencies ranging
from 1.1 to 12.6%.
In the SOC-level LCM, full models with two through
five classes had BIC of 54,213, 54,162, 54,158, and 54,193;
and partial models with two through seven classes had BIC
of 54,006, 53,994, 53,967, 53,965, 53,937, and 53,940,
respectively. The four-class full and six-class partial
models were selected based on the best fit by BIC. Class
labels were assigned subjectively based on conditional
probabilities, with a mild and moderate neuropsychiatric
class identified in each, as shown in Fig. 2.
The partial model had entropy of 0.560 and a non-sig-
nificant overall univariate residual (v2 = 0.003, p[ 0.05).
Despite non-significant pairwise bivariate residuals (v2\
1.96, p[ 0.05 for all comparisons), the overall bivariate
residual was significant (v2 = 13.79, p[ 0.05), with evi-
dence on subsequent pseudoclass testing of significant
residual conditional dependence between indicator pairs
for the respiratory and vascular SOCs, and for the hepa-
tobiliary and metabolic SOCs in the moderate neuropsy-
chiatric class; and between indicator pairs for the cardiac
and renal SOCs in the multi-system class. In contrast, the
full model had entropy of 0.872, and non-significant
Fig. 1 Study cases in the
primary and control datasets.
AP atovaquone-proguanil, CQ
chloroquine, DX doxycycline,
LP loperamide, MQ mefloquine
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overall univariate and bivariate as well as pairwise
bivariate residuals.
3.2 HLGT-Level Modeling
Assigning subjects to their most-likely class, prevalence of
reported reactions by HLGT in both the moderate and mild
neuropsychiatric classes, in the partial and full models, by
most-likely class and overall without regard to class
assignment, is shown in Table 4. Of the 42 neuropsychi-
atric HLGTs, anxiety disorders and symptoms, sleep dis-
orders and disturbances, and neurological disorders not
elsewhere classified (NEC) were most prevalent across
model classes, but these HLGTs and nine others had evi-
dence of significant differential measurement across both
the mild and moderate neuropsychiatric classes in both the
full and partial models and were excluded from further
consideration. Of the remaining 30, eight occurred at 2%
prevalence or greater and exhibited no significant differ-
ential measurement in the moderate neuropsychiatric class
in both the full and partial models, and these were selected
as indicators for the final LCM. HLGTs selected for the
final model included communication disorders and distur-
bances; deliria (including confusion); dementia and
amnestic conditions; depressed mood disorders and dis-
turbances; neuromuscular disorders; peripheral neu-
ropathies; psychiatric disorders NEC; and seizures
(including subtypes).
In the HLGT-level LCM, models with two through
four classes had BIC of 11,908, 11,972, and 12,038,
respectively. The two-class model was selected, and had
entropy of 0.971, and non-significant overall univariate
and bivariate as well as pairwise bivariate residuals. A
neuropsychiatric syndrome class with an overall preva-
lence of 4.3% was identified without evidence of signif-
icant differential measurement by drug for any HLGT-
level indicator. In contrast, the non-syndrome class
demonstrated evidence of significant differential mea-
surement for three HLGT-level indicators: deliria (in-
cluding confusion), dementia and amnestic conditions,
and depressed mood disorders and disturbances. Among
cases in the most-likely non-syndrome class, simple
logistic regression showed these indicators were signifi-
cantly more likely to be reported with mefloquine, and
significantly less likely to be reported with doxycycline.
Conditional probabilities of HLGT-level indicators for the
syndrome and non-syndrome class are reported in
Table 5.
Table 1 Sex and age groups of
study cases in the primary and
control datasets, by drug
Primary dataset Control dataset
Mefloquine Atovaquine-proguanil Doxycycline Chloroquine Loperamide
n (%) n (%) n (%) n (%) n (%)
All cases 933 (100) 450 (100) 3949 (100) 422 (100) 6724 (100)
Sex
Male 489 (52.4) 198 (44.0) 1506 (38.1) 109 (25.8) 3306 (49.2)
Female 418 (44.8) 224 (49.8) 2308 (58.5) 300 (71.1) 3194 (47.5)
Unknown 26 (2.8) 28 (6.2) 135 (3.4) 13 (3.1) 224 (3.3)
Age group, years
\18 51 (5.5) 35 (7.8) 192 (4.9) 22 (5.2) 181 (2.7)
18–65 595 (63.8) 225 (50) 1917 (48.5) 216 (51.2) 2659 (39.5)
65? 287 (30.8) 190 (42.2) 1840 (46.6) 184 (43.6) 3884 (57.8)
Across all strata, proportions varied significantly by drug, in both the primary dataset and in the pooled data
overall (p\ 0.05 by v2 test)
Table 2 Drug indication of




n (%) n (%) n (%)
All cases 933 (100) 450 (100) 3949 (100)
Drug indication
Malaria prophylaxis 294 (31.5) 278 (61.8) 30 (0.8)
Other or unknown 639 (65.5) 172 (38.2) 3,919 (99.2)
Proportions varied significantly by drug (p\ 0.001 by v2 test)
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Based on the most-likely class assignment, the preva-
lence of the syndrome class in the primary study dataset
was 10.3% with mefloquine, 2.0% with atovaquone-pro-
guanil, and 3.5% with doxycycline. On three-step testing,
the syndrome class was positively associated with meflo-
quine (OR 3.92, 95% CI 2.91–5.28, p\ 0.001), and neg-
atively associated with atovaquone-proguanil (OR 0.35,
95% CI 0.14–0.85, p = 0.020) and doxycycline (OR 0.38,
95% CI 0.28–.51, p\0.001). Applying the fitted model to
the control dataset, based on the most-likely class assign-
ment, the prevalence of the syndrome was 3.3% with
chloroquine and 6.0% with loperamide. However, on three-
step testing, there was no significant association of the
syndrome with chloroquine (OR = 0.46, 95% CI 0.17–1.28,
p = 0.138) or with loperamide (OR = 2.172, 95% CI
0.78–6.04, p = 0.138).
3.3 Most-Likely Class Modeling
On post-hoc analysis of the study dataset, assigning cases
to their most-likely class, among the 5095 cases assigned to
the non-syndrome class, the five most commonly reported
HLGTs across all 15 study SOCs were gastrointestinal
signs and symptoms; neurological disorders NEC; epider-
mal and dermal conditions; respiratory disorders NEC; and
anxiety disorders and symptoms. In contrast, among the
237 cases assigned to the most-likely syndrome class, the
five most commonly reported HLGTs were deliria
(including confusion); neurological disorders NEC; anxiety
disorders and symptoms; sleep disorders and disturbances;
and depressed mood disorders and disturbances. The
prevalence of these most commonly reported syndrome
HLGTs together with the most commonly reported reac-
tions, by PT, within each (with greater than 5% overall
prevalence), by most-likely class, are listed in Table 6,
along with ORs for reporting each HLGT in the most-likely
syndrome vs. non-syndrome class.
Among the study dataset, among cases assigned to the
most-likely class, the proportion of cases by drug in the
syndrome class did not vary significantly by v2 test by age
group (\18 years, 18–65 years, and 65? years) for
mefloquine (p = 0.292), atovaquone-proguanil (p = 0.073),
or doxycycline (p = 0.151). In contrast, while the propor-
tion of cases in the syndrome class by drug did not vary
significantly by v2 test by sex for atovaquone-proguanil
(p = 0.184), they did vary significantly by sex for meflo-
quine (p = 0.001) and doxycycline (p = 0.002), being
strongly associated in each with male sex by simple logistic
regression (OR 2.15, 95% CI 1.37–3.38, and OR 1.70, 95%
CI 1.20–2.41, respectively).
The proportion of cases by drug in the syndrome class
also varied significantly by v2 test by reported indication
for mefloquine (p\0.001), being strongly associated with
malaria prophylaxis (OR 2.29, 95% CI 1.50–3.51) by the
most-likely syndrome class assignment, an association not
seen with atovaquone-proguanil (p = 0.318) or, by
Table 3 Prevalence of reported reactions by MedDRA SOC, by drug and overall, primary dataset
Mefloquine Atovaquone-proguanil Doxycycline Overall
n (%) n (%) n (%) n (%)
Any SOC 933 (100) 450 (100) 3949 (100) 5332 (100)
Blood and lymphatic system disorders 55 (5.6) 42 (9.3) 487 (12.3) 584 (11.0)
Cardiac disorders 136 (14.6) 19 (4.2) 473 (12.0) 628 (11.8)
Ear and labyrinth disordersa 33 (3.5) 6 (1.3) 70 (1.8) 109 (2.0)
Endocrine disordersa 7 (0.8) 2 (0.4) 70 (1.8) 79 (1.5)
Eye disorders 67 (7.2) 25 (5.6) 212 (5.4) 304 (5.7)
Gastrointestinal disorders 233 (25.0) 123 (27.3) 1242 (31.4) 1598 (30.0)
Hepatobiliary disorders 36 (3.9) 26 (5.8) 326 (8.3) 388 (7.3)
Metabolism and nutrition disorders 67 (7.2) 33 (7.3) 447 (11.3) 547 (10.3)
Musculoskeletal and connective tissue disorders 117 (12.5) 33 (7.3) 614 (15.6) 764 (14.3)
Nervous system disorders 438 (47.0) 131 (29.1) 1193 (30.2) 1762 (33.0)
Psychiatric disorders 527 (56.5) 95 (21.1) 805 (20.4) 1427 (26.8)
Renal and urinary disorders 41 (4.4) 20 (4.4) 381 (9.6) 442 (8.3)
Respiratory, thoracic, and mediastinal disorders 127 (13.6) 45 (10.0) 767 (19.4) 939 (17.6)
Skin and subcutaneous tissue disorders 148 (15.9) 106 (23.6) 790 (20.0) 1044 (19.6)
Vascular disorders 66 (7.1) 26 (5.8) 618 (15.6) 710 (13.3)
MedDRA Medical Dictionary for Regulatory Activities, SOC system organ class
Across all SOCs, proportions varied significantly by drug (p\ 0.05 by v2 test)
a SOC with 2.0% prevalence or less overall excluded from subsequent SOC-level analysis
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Fischer’s exact test, with doxycycline (p = 0.426). Overall,
based on the most-likely class assignment, the prevalence
of the syndrome class in the primary study dataset among
cases with a reported indication of malaria prophylaxis was
16.0% with mefloquine, 2.5% with atovaquone-proguanil,
and 0% with doxycycline.
Fig. 2 Conditional probabilities, SOC-level models. a Fully condi-
tionally dependent (full) model. b Partially conditionally dependent
(partial) model. blood blood and lymphatic system disorders, cardiac
cardiac disorders, derm skin and subcutaneous tissue disorders, eye
eye disorders, gastro gastrointestinal disorders, hep hepatobiliary
disorders, metab metabolism and nutrition disorders, ms
musculoskeletal and connective tissue disorders, neuro nervous
system disorders, psych psychiatric disorders, renal renal and urinary
disorders, resp respiratory, thoracic, and mediastinal disorders,
vascular vascular disorders. Line thickness is proportional to class
membership conditional probability. SOC system organ class
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Table 4 Prevalence of reported reactions by MedDRA neuropsychiatric HLGT, by SOC-level latent class model most-likely neuropsychiatric
class, and overall
Moderate Mild Overall
Partial Full Partial Full
n (%) n (%) n (%) n (%) n (%)
Any neuropsychiatric HLGT 511 (93.4) 465 (92.0) 1577 (89.6) 1878 (43.0) 2429 (45.6)
Adjustment disorders (including subtypes) 2a (0.4) 2a (0.43) 4a (0.2) 3a (0.1) 11 (0.21)
Anxiety disorders and symptoms 145a (28.4) 149a (32.0) 369a (20.1) 379a (8.7) 604 (11.3)
Changes in physical activity 15a (2.9) 18a (3.9) 40a (2.3) 38a (0.9) 67 (1.3)
CNS infections 11 (2.2) 9 (1.9) 18 (1.0) 23 (0.5) 39 (0.7)
CNS vascular disorders 29 (5.7) 24a (5.2) 68 (3.9) 81 (1.9) 134 (2.5)
Cognitive and attention disorders and disturbances 45a (8.8) 46a (9.9) 103a (5.8) 102a (2.3) 171 (3.2)
Communication disorders and disturbancesb 31 (6.1) 34 (7.3) 75 (4.3) 73 (1.7) 126 (2.4)
Congenital neurological disorders 3 (0.6) 3 (0.6) 3 (0.2) 3 (0.1) 8 (0.2)
Cranial nerve disorders (excluding neoplasms) 35a (6.8) 35a (7.5) 99a (5.6) 109a (2.5) 167 (3.1)
Deliria (including confusion) b 60 (11.7) 55 (11.8) 128a (7.3) 135a (3.1) 219 (4.1)
Dementia and amnestic conditionsb 37 (7.2) 42 (9.0) 92a (5.2) 92a (2.1) 161 (3.0)
Demyelinating disorders 5 (1.0) 2 (0.4) 19 (1.1) 26 (0.6) 32 (0.6)
Depressed mood disorders and disturbancesb 89 (17.4) 85 (18.3) 184a (10.4) 192a (4.4) 340 (6.4)
Developmental disorders NEC 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.0) 1 (0.0)
Dissociative disorders 6 (1.2) 6 (1.3) 16a (0.9) 16a (0.4) 25 (0.5)
Disturbances in thinking and perception 41a (8.0) 43a (9.2) 176a (10.0) 179a (4.1) 242 (4.5)
Eating disorders and disturbances 29 (5.7) 25 (5.4) 31 (1.8) 36 (0.8) 73 (1.4)
Encephalopathies 15 (2.9) 16 (3.4) 16 (0.9) 20 (0.5) 43 (0.8)
Headaches 131a (25.6) 121a (26.0) 190 (10.8) 242a (5.6) 415 (7.8)
Impulse control disorders NEC 2 (0.4) 2 (0.4) 12 (0.7) 12 (0.3) 16 (0.3)
Increased intracranial pressure 11 (2.2) 9 (1.9) 50 (2.8) 54 (1.2) 70 (1.3)
Manic and bipolar mood disorders 7 (1.4) 10 (2.2) 40a (2.3) 40a (0.9) 55 (1.0)
Mood disorders and disturbances NEC 73a (14.3) 74a (15.9) 193a (11.0) 203a (4.6) 318 (6.0)
Movement disorders (including parkinsonism) 61a (11.9) 62a (13.3) 127 (7.2) 141a (3.2) 230 (4.3)
Nervous system neoplasms benign 0 (0.0) 1 (0.2) 2 (0.1) 2 (0.0) 4 (0.1)
Nervous system neoplasms malignant 0 (0.0) 0 (0.0) 2 (0.1) 3 (0.1) 6 (0.1)
Neurological disorders of the eye 47a (9.2) 39a (8.4) 112 (6.4) 130a (3.0) 204 (3.8)
Neurological disorders NEC 268a (52.4) 253a (54.4) 582a (33.0) 736a (16.9) 1089 (20.4)
Neuromuscular disordersb 43 (8.4) 40 (8.6) 67 (3.8) 82a (1.9) 163 (3.1)
Peripheral neuropathiesb 30 (5.9) 28 (6.0) 32 (1.8) 44 (1.0) 116 (2.2)
Personality disorders and disturbances 20a (3.9) 27a (5.8) 153a (8.7) 149a (3.4) 188 (3.5)
Psychiatric and behavioral symptoms 26a (5.1) 30 (6.4) 77a (4.4) 76a (1.7) 119 (2.2)
Psychiatric disorders NECb 47 (9.2) 44 (9.5) 71 (4.0) 74a (1.7) 148 (2.8)
Schizophrenia and other psychotic disorders 17a (3.3) 13a (2.8) 82a (4.7) 85a (2.0) 109 (2.0)
Seizures (including subtypes) b 40 (7.8) 37 (8.0) 136 (7.7) 151 (3.5) 203 (3.8)
Sexual dysfunctions and disturbances 13 (2.5) 11 (2.4) 18 (1.0) 19 (0.4) 46 (0.9)
Sleep disorders and disturbances 119a (23.3) 113a (24.3) 273a (15.5) 291a (6.7) 454 (8.5)
Sleep disturbances (including subtypes)c 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.0) 1 (0.0)
Somatoform and factitious disorders 20 (3.9) 19 (4.1) 16 (0.9) 15 (0.3) 48 (0.9)
Spinal cord and nerve root disorders 16 (3.1) 13 (2.8) 7 (0.4) 10 (0.2) 57 (1.1)
Structural brain disorders 8 (1.6) 4 (0.9) 10 (0.6) 12 (0.3) 34 (0.6)
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4 Discussion
This analysis has found, among reports of adverse events
associated with common antimalarial drugs, evidence of a
distinct neuropsychiatric syndrome class that is strongly
associated with mefloquine use. This syndrome class is
defined by a very high probability (82.7%) of symptoms of
deliria, including confusion and disorientation, and a
moderate probability of other serious psychiatric and neu-
rologic symptoms including dementia and amnestic con-
ditions (18.6%), and seizures (18.1%). Among reports of
adverse events associated with drugs used for the prophy-
laxis of chloroquine-resistant malaria, this syndrome class
is nearly exclusive to the use of mefloquine, and occurs in
approximately one in six such reports.
Intriguingly, the characteristic symptoms of this syn-
drome class, including confusion, amnesia, and seizure,
were among the earliest reported, serious adverse neu-
ropsychiatric effects of mefloquine noted in the literature
following the drug’s initial European licensing in the mid-
1980s. Initial case reports described a syndrome of acute
brain or toxic encephalopathy, typically with confusion and
seizure [26–28]. Isolated amnesia was also reported [29], as
was psychosis associated with symptoms of confusion [30].
An early case series, which emphasized neurological
reactions, also noted that difficulties with concentration
were a common feature [31]. Unlike other possibly more
subjective neuropsychiatric symptoms, these severe neu-
ropsychiatric reactions, suggestive of organic central ner-
vous system dysfunction, would be expected to have been
subject to minimal reporting bias or nocebo effect.
In this study, among reports of adverse events, this
syndrome is commonly accompanied by clinical features
that are considered prodromal when associated with
mefloquine use, including sleep disturbance, abnormal
dreams, anxiety, and depression, as well as neurological
symptoms such as dizziness, vertigo, and paresthesias [2].
While this study’s methods could not determine whether
any of these reported symptoms preceded the more serious
characteristic symptoms of this syndrome class, such pro-
gression would be consistent with case reports [13–15] and
regulatory warnings describing certain neuropsychiatric
symptoms as prodromal to more serious events from the
use of mefloquine. Similarly, while this study’s methods
could not determine the chronicity of these symptoms, their
persistence would be consistent with the results of a recent
cohort study of reported mefloquine adverse events, which
found symptoms including mood disturbance, cognitive
dysfunction, and nightmares occasionally persisting for
months to years after the initial adverse event report [32].
Interestingly, this study found that this syndrome class is
more common among reports of adverse events from male
users than female users of mefloquine. This contrasts with
other published findings, in which milder neuropsychiatric
Table 4 continued
Moderate Mild Overall
Partial Full Partial Full
n (%) n (%) n (%) n (%) n (%)
Suicidal and self-injurious behavior 37a (7.2) 34a (7.3) 167a (9.5) 169a (3.9) 221 (4.1)
CNS central nervous system, HLGT high-level group term,MedDRAMedical Dictionary for Regulatory Activities, NEC not elsewhere classified,
SOC system organ class
a HLGT-level indicators with evidence of significant differential measurement by drug in the model class
b HLGT-level indicator selected for the final model
c Includes only those reactions not primarily categorized in the psychiatric disorders SOC
Table 5 Conditional
probabilities by class, two-class
HLGT-level latent class model
Syndrome Non-syndrome
Communication disorders and disturbances 0.182 0.017
Deliria (including confusion) 0.827 0.006
Dementia and amnestic conditions 0.186 0.023
Depressed mood disorders and disturbances 0.318 0.052
Neuromuscular disorders 0.090 0.028
Peripheral neuropathies 0.082 0.019
Psychiatric disorders NEC 0.314 0.015
Seizures (including subtypes) 0.181 0.032
HLGT high-level group term, NEC not elsewhere classified
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symptoms, some of which might be considered prodromal,
are more commonly reported among female users of the
drug [33, 34]. While the reasons for this are unclear, it is
plausible that this finding could reflect a greater propensity
among certain male individuals, such as military personnel,
to fail to discontinue mefloquine at the onset of prodromal
symptoms [11], consequently risking the development of
more serious neuropsychiatric effects [2].
4.1 Limitations
This study has several important limitations that require the
results to be interpreted with caution. This study relied on
reported drug adverse event data within the FAERS data-
base, which is known to suffer from significantly incom-
plete reporting [35, 36], and the accuracy of these data,
including suspect drug elements, is often questionable [35].
Partially to address the potential for suspect drug misat-
tribution, this study included reports in the analysis even
when the drug was listed as non-suspect. This had the
benefit of significantly increasing the sample size, but
possibly as a consequence, there were a high number of
cases of the neuropsychiatric syndrome class associated
with both doxycycline and loperamide. In contrast, in the
post-hoc analysis of the study dataset, based on most-likely
class assignment, there were no cases of the syndrome class
among those in whom doxycycline was reported as indi-
cated for malaria prophylaxis.
This study employed highly conservative methods for
identifying residual conditional dependence in the partial
model, as well as differential measurement in the SOC- and
HLGT-level models. While this was done for computa-
tional simplicity, it may have had the effect of over-iden-
tification. Additionally, such methods, intended to exclude
from the final LCM those HLGT-level indicators with any
evidence of differential measurement by drug, essentially
excluded from the syndrome class any reactions that might
be uniquely associated with mefloquine use. While these
methods were deemed desirable to guard against the risk
that over-reporting of certain symptoms, such as from a
nocebo effect with mefloquine use, would affect the
validity of the results, this had the consequence that certain
more serious reactions associated with mefloquine in later
case reports, such as psychosis [14, 15], were not included
among the characteristic features of the syndrome. Addi-
tionally, we did not specifically assess for evidence of
Table 6 Prevalence of most
commonly reported HLGTs and
reactions within each, by PT,
among cases assigned to most-
likely syndrome class, two-class
HLGT-level latent class model,
by class
Syndrome Non-syndrome
n (%) n (%) OR (95% CI)
All cases 237 (100) 5095 (100)
Deliria (including confusion) 181 (76.4) 16 (0.3) 1039.2 (582.1–1855.4)
Confusional state 114 (48.1) 11 (0.2)
Disorientation 55 (23.2) 5 (0.1)
Delirium 25 (10.5) 0 (0.0)
Neurological disorders NEC 109 (46.0) 821 (16.1) 4.3 (3.3–5.6)
Dizziness 41 (17.3) 234 (4.6)
Hypoesthesia 17 (7.2) 128 (2.5)
Paresthesia 16 (6.8) 93 (1.8)
Vertigo 15 (6.3) 52 (1.0)
Anxiety disorders and symptoms 98 (41.4) 412 (8.1) 7.7 (5.8–10.2)
Anxiety 55 (23.2) 245 (4.8)
Agitation 34 (14.3) 50 (1.0)
Panic attack 26 (11.0) 101 (2.0)
Sleep disorders and disturbances 84 (35.4) 318 (6.2) 7.9 (5.9–10.6)
Insomnia 39 (16.5) 147 (2.9)
Somnolence 21 (8.9) 47 (0.9)
Abnormal dreams 19 (8.0) 50 (1.0)
Nightmare 18 (7.6) 65 (1.3)
Sleep disorder 16 (6.8) 26 (0.5)
Depressed mood disturbances and disorders 74 (31.2) 238 (4.7) 8.9 (6.6–12.1)
Depression 62 (26.2) 185 (3.6)
CI confidence interval, HLGT high-level group term, NEC not elsewhere classified, OR odds ratio, PT
preferred term
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differential measurement by age, sex, or drug indication,
which may limit the validity of inference on these
covariates.
Despite these limitations, these results are nonetheless
useful and intriguing, and suggest that case finding for
more serious neuropsychiatric reactions to mefloquine may
be improved through the identification of characteristic
reactions that are highly specific to the identified syndrome
class. In this respect, it is noteworthy that 181 of the 197
cases (91.9%) in the study dataset reporting one or more
reactions within the HLGT that included the PTs confu-
sional state, disorientation, and delirium, were assigned by
the model to the most-likely syndrome class, and that this
association was exceedingly strong and significant (OR =
1039.2, 95% CI 581.1–1855.4, p\ 0.001). These results
suggest that among those users reporting adverse neu-
ropsychiatric reactions to common antimalarial medica-
tions, and for whom no other likely cause, such as
concussion, may be identified for these symptoms, such
reactions should be considered nearly pathognomonic for
this syndrome class.
5 Conclusions
Early reports of adverse effects from mefloquine descri-
bed a clinical syndrome characterized principally by
confusion, amnesia, and seizure. This analysis has found
evidence of a similar syndrome class in subsequent
reports of adverse events from common antimalarial drugs
within the FAERS database. This syndrome class is
strongly and significantly associated with mefloquine use,
particularly in prophylaxis, and is not strongly associated
with reports from other common antimalarial drugs when
used in the prophylaxis and treatment of chloroquine-re-
sistant malaria. The association of this specific and severe
syndrome class with common symptoms that are consid-
ered prodromal, including anxiety, depression, sleep dis-
turbance, and abnormal dreams, should reinforce existing
regulatory guidance that the drug should be discontinued
at their onset. The clinical identification of additional
features associated with this syndrome class, including
neurological symptoms such as dizziness, vertigo, and
paresthesias, may aid in improving case finding in phar-
macovigilance studies of more serious adverse reactions
to the drug.
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